New cell therapy takes on Hard-to-Treat multiple myeloma

NCT ID NCT07100067

Recruiting now Disease control Sponsor: Nanjing Legend Biotech Co. Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 24, 2026 · Updated 19 times

Summary

This study is testing an experimental cell therapy called LCAR-F33S in 35 adults with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see how well the therapy works against the cancer. Participants will receive a one-time infusion of their own modified immune cells.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA(MM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beijing Boren Hospital
NOT_YET_RECRUITING

Beijing, China

Contact Email: •••••@•••••
Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, China
Institute of Hematology & Blood Diseases Hospital
RECRUITING

Tianjin, China

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Wuhan Union Hospital
RECRUITING

Wuhan, China

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

RELAPSED/REFRACTORY MULTIPLE MYELOMA(MM)